NUROSENE CHIEF SCIENCE OFFICER PRESENTS AT LEADING DRUG DEVELOPMENT FORUM

TORONTO, Dec. 6, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions developed by NetraMark (a wholly owned subsidiary of the Company) announces that Dr. Joseph Geraci, Nurosene's Chief Science Officer, will be participating  in the Advancing Drug Development Forum on December 14th, 2022 in Boston, MA.

This event strives to attract and stimulate dialogue / networking with key opinion leaders in biotech and pharma, executive leadership, senior directors, consultants, and a close network of Contract Research Organizations (CROs) and Contract Development and Manufacturing Companies (CDMOs) to further explore together novel solutions, promising technology breakthroughs and hearing how the entrepreneurial industry leaders are introducing and incorporating novel approaches in small molecule drug development, changing timelines and ROIs. The Forum provides a great opportunity for Sponsors and other industry partners to learn about AI solutions for the Pharmaceutical industry.

Dr. Joseph Geraci will join Keith Parent, CEO of Court Square Group, in a panel discussion moderated by Forum Chair Roger Franchette entitled "Drowning in Data – Disruptive AI Technologies to Improve Development."

"I am very excited to participate in the Advancing Drug Development Forum panel discussion to share how different AI strategies can bring innovation to clinical trials be it from improving Sponsor visibility into their patients or improving the regulatory submission process," said Dr. Joseph Geraci, Chief Scientific Officer of Nurosene.

Link to conference agenda and registration:  https://advdrug.org/agenda-%26-registration

About Nurosene

Nurosene is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions developed by NetraMark (a wholly owned subsidiary of the Company) and targeted at the Pharmaceutical industry.

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

 The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

Josh Spiegel, President, NetraMark | [email protected] | 917-721-9033